Gilead Announces Senior Management Change
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Alessandro Riva, MD, Executive Vice President, Oncology Therapeutics, has decided to leave the company to pursue another opportunity. Dr. Riva will remain at Gilead through the end of the month. The company has commenced a search for his successor.
Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutics Area Head. During his tenure, he has been instrumental in expanding the company’s oncology programs, playing a critical role in the acquisition of Kite Pharma and guiding the strategy and development of Gilead’s broader oncology pipeline.
“Under Alessandro’s oversight, Gilead has expanded its work in the field of oncology and established itself as the leader in cell therapy with the acquisition of Kite,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development. “We are well-positioned to continue to grow, and I am confident in the ability of Gilead and Kite to advance our pipeline of novel therapeutics for people living with cancer.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
Amy Flood, Media
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
BARTEK-INGREDIENTS21.3.2019 23:37:07 CET | Pressemeddelelse
Bartek Ingredients Expands Leadership Team
MAJESCO/HANSARD-GLOBAL21.3.2019 21:32:10 CET | Pressemeddelelse
Hansard Global Plc Selects SaaS-Based Majesco LifePlus Solutions to Transform Their Business
CA-RESMED21.3.2019 21:07:09 CET | Pressemeddelelse
ResMed to Host an Investor Meeting on April 4, 2019
QATARDEBATE21.3.2019 16:05:13 CET | Pressemeddelelse
Her Excellency Sheikha Hind Attends International Universities Arabic Debating Championship Closing Ceremony
CA-TAULIA21.3.2019 16:02:03 CET | Pressemeddelelse
Taulia Enhances Platform with New Artificial Intelligence Capabilities in a World First for Working Capital Solutions
PA-CITRUS21.3.2019 15:23:09 CET | Pressemeddelelse
Life-Sciences and Healthcare Communications Leaders John “Zeke” Czekanski and Scott Roberts Join Citrus Global Healthcare Communications Group as Managing Partners
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum